Is Kratom an Opioid? Here's What the Science Actually Says

The Short Answer (and Why It's Complicated)

"Is kratom an opioid?" is the most common question I get. And the honest answer is: it depends on who you ask and how strictly you define "opioid."

If you define opioid as "anything that binds to opioid receptors," then yes, kratom qualifies. But by that logic, chocolate and exercise are opioidergic too, since they trigger endorphin release at those same receptors.

If you define opioid as the class of drugs that includes morphine, oxycodone, heroin, and fentanyl, then no. Kratom is pharmacologically different in ways that really matter — especially when it comes to the risk of fatal overdose.

The real answer sits in the middle, and I think it's important to understand the nuance. Your stance on this question probably shouldn't be "yes" or "no." It should be "it's more complicated than that." Let me break it down.

What Are Opioids, Exactly?

Before we can figure out where kratom fits, we need to define our terms.

Opiates are natural compounds derived from the opium poppy. Morphine and codeine are opiates.

Opioids is a broader term that includes opiates plus synthetic and semi-synthetic drugs designed to act on the same receptors. Oxycodone, hydrocodone, fentanyl, heroin — these are all opioids.

What they have in common is that they bind to mu-opioid receptors in your brain and body. When these receptors are activated, you get pain relief, euphoria, sedation, and (at high enough doses) respiratory depression. That last one is what kills people in opioid overdoses — your brain literally forgets to tell your lungs to breathe.

So where does kratom fit in this picture? It's complicated because kratom does interact with those same receptors. But it does so in a fundamentally different way.

How Kratom Interacts With Opioid Receptors

Kratom contains over 40 alkaloids, but two do most of the heavy lifting: mitragynine and 7-hydroxymitragynine.

Mitragynine is the most abundant alkaloid, making up about 60-66% of the alkaloid content. It's a partial agonist at the mu-opioid receptor. I'll explain what that means in a second. It also interacts with adrenergic receptors (which influence energy and focus) and serotonin receptors (which affect mood). This multi-receptor activity is why kratom feels different from a pure opioid.

7-hydroxymitragynine is present in much smaller quantities but is significantly more potent at the mu-opioid receptor. It's thought to be responsible for much of kratom's pain-relieving and sedating effects at higher doses.

Here's what makes kratom unusual: it's not just hitting one receptor system. It's interacting with opioid, adrenergic, serotonin, and dopamine systems simultaneously. This is why low doses of kratom feel stimulating (more like coffee, which makes sense since kratom is in the same botanical family as coffee) while higher doses feel more sedating and pain-relieving.

No classical opioid works this way. Morphine doesn't give you energy at low doses. Oxycodone doesn't make you more focused and alert. This multi-mechanism action is a big reason why many researchers resist calling kratom simply "an opioid."

The Key Difference: Partial vs Full Agonists

This is the most important concept in this whole debate, so stick with me.

Traditional opioids like morphine and fentanyl are full agonists at the mu-opioid receptor. That means the more you take, the stronger the effect — including respiratory depression. There's no built-in ceiling. This is why opioid overdoses are so deadly. Take enough and your breathing simply stops.

Kratom's main alkaloid, mitragynine, is a partial agonist. It activates the receptor, but not fully. There's a ceiling effect. Past a certain point, taking more kratom doesn't increase the opioid-like effects proportionally. You just get more side effects — nausea, the wobbles, sedation — but not the escalating respiratory depression that makes traditional opioids lethal.

This is the same principle behind buprenorphine (Suboxone), which is used to treat opioid addiction. Buprenorphine is also a partial agonist. It activates opioid receptors enough to prevent withdrawal but has a ceiling that makes overdose much less likely. Kratom's mechanism is similar in concept, though the specific pharmacology differs.

Research published in the last few years has also shown that kratom alkaloids are "biased agonists" — they preferentially activate the G-protein signaling pathway over the beta-arrestin pathway. In plain English, this means they may produce pain relief with less respiratory depression and less constipation than traditional opioids. This is actually what a lot of pharmaceutical companies are trying to engineer in new pain drugs. Kratom does it naturally.

Why the DEA and FDA Call It an Opioid (and Why Researchers Push Back)

In 2016, the DEA tried to emergency-schedule kratom as a Schedule I substance. The public backlash was massive and they backed off. But the FDA has continued to push the narrative that kratom is an opioid.

The FDA's argument is based primarily on a 2018 computational analysis that used a 3D model to show kratom alkaloids bind to opioid receptors. Former FDA Commissioner Scott Gottlieb stated that kratom's compounds were "opioids" based on this modeling.

Researchers have pushed back hard on this. Dr. Jack Henningfield, a Johns Hopkins pharmacologist who was hired by the American Kratom Association to do an independent analysis, concluded that kratom has a low potential for abuse and doesn't warrant scheduling as a controlled substance. Multiple other researchers have published papers arguing that calling kratom an opioid is misleading because it ignores the critical pharmacological differences.

The concern from the research community is that labeling kratom as an opioid could lead to its prohibition, cutting off access for the millions of Americans who use it — many of whom turned to kratom specifically to get away from actual opioids.

Some researchers have proposed the term "atypical opioid" or "opioidergic compound" to acknowledge the receptor interaction without equating kratom to drugs like fentanyl. That feels more honest to me, though I understand why the term still makes some people uncomfortable.

Kratom vs Opioids: A Direct Comparison

Let's put kratom and traditional opioids side by side on the factors that actually matter.

The respiratory depression difference is the big one. That's what kills about 80,000 Americans every year from opioid overdoses. Kratom's partial agonist mechanism makes this type of fatal overdose extraordinarily unlikely with kratom alone. When kratom-associated deaths occur, toxicology reports almost always find other substances involved.

Why This Classification Debate Matters

This isn't just an academic argument. The classification of kratom has real consequences for real people.

Millions of Americans use kratom. Many of them are former opioid users who found that kratom helped them stop using pills or heroin. The American Kratom Association estimates 10-15 million regular users in the US.

If kratom gets classified as a Schedule I controlled substance (like heroin), these people lose access overnight. No prescription pathway. No legal purchase. Many would likely return to the substances they were trying to escape.

On the other hand, kratom being completely unregulated isn't ideal either. Without quality standards, bad product gets into the market. People take contaminated kratom and have bad reactions, which then gets blamed on kratom itself. It's a feedback loop that hurts everyone.

The sweet spot, in my opinion and in the opinion of most kratom advocates, is the Kratom Consumer Protection Act (KCPA). This state-level legislation regulates kratom without banning it — requiring lab testing, age verification, proper labeling, and prohibiting adulterated product. Several states have already passed versions of it. Check our kratom legality page to see where your state stands.

My Personal Perspective

I came to kratom from pharmaceutical pain management. I'd been on and off various prescription painkillers for years. I know what opioids feel like. I know what opioid withdrawal feels like. I know what it's like to have a doctor hand you a script and tell you to figure it out.

Kratom is not the same thing. I'll say that plainly and without hesitation.

Does it hit some of the same receptors? Sure. But the experience is fundamentally different. The ceiling effect is real — I can't just keep taking more and more and getting higher and higher. At some point, more kratom just means nausea and the wobbles. There's a built-in brake that prescription opioids don't have.

The dependence is real. I won't pretend it isn't. But managing kratom dependence has been orders of magnitude easier than managing prescription painkiller dependence. The withdrawal is uncomfortable, not devastating. The cravings are mild, not all-consuming.

Is kratom an opioid? I think calling it one is technically defensible but practically misleading. It's like calling a bicycle a motorcycle because they both have two wheels. The category is right but the implication is wrong.

Current Research and Future Outlook

The good news is that kratom research has accelerated dramatically in the last few years. The National Institute on Drug Abuse (NIDA) has funded multiple studies on kratom alkaloids. Researchers at institutions like the University of Florida, Columbia University, and Memorial Sloan Kettering are actively studying mitragynine and its derivatives.

Some of the most promising research focuses on synthetic versions of kratom alkaloids that could be developed into new pain medications — drugs that provide pain relief without the respiratory depression risk of current opioids. If this pans out, the very plant that the FDA wants to ban could end up being the blueprint for safer pain management.

There's also growing research into kratom's potential role in opioid harm reduction. Studies are examining whether kratom can be a viable tool for helping people taper off harder opioids, similar to how methadone and buprenorphine are used but without requiring a clinic visit or prescription.

The next few years are going to be important for kratom's legal and scientific status. More data means better policy. And better policy means safer access for the people who benefit from this plant.

If you're interested in trying kratom yourself, start with tested, quality product from reputable vendors. The vendor matters more than most people realize.

Frequently Asked Questions